These data strongly suggest that neutralizing anti-NGAL-R antibodies induce CLL cell death—perhaps by blocking the interaction between endogenous NGAL and its surface receptor. The gene discussed is LCN2; the disease is B-cell chronic lymphocytic leukemia.